vs

Side-by-side financial comparison of CuriosityStream Inc. (CURI) and Monte Rosa Therapeutics, Inc. (GLUE). Click either name above to swap in a different company.

CuriosityStream Inc. is the larger business by last-quarter revenue ($19.2M vs $12.8M, roughly 1.5× Monte Rosa Therapeutics, Inc.). CuriosityStream Inc. runs the higher net margin — -19.7% vs -212.1%, a 192.4% gap on every dollar of revenue. On growth, Monte Rosa Therapeutics, Inc. posted the faster year-over-year revenue change (38.5% vs 35.8%). Monte Rosa Therapeutics, Inc. produced more free cash flow last quarter ($99.8M vs $3.9M).

Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.

Monte Rosa Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of targeted molecular glue degrader therapies. Its pipeline addresses unmet medical needs across oncology, rare genetic disorders and immunological diseases, with operations focused on advancing novel treatments for global patient populations.

CURI vs GLUE — Head-to-Head

Bigger by revenue
CURI
CURI
1.5× larger
CURI
$19.2M
$12.8M
GLUE
Growing faster (revenue YoY)
GLUE
GLUE
+2.7% gap
GLUE
38.5%
35.8%
CURI
Higher net margin
CURI
CURI
192.4% more per $
CURI
-19.7%
-212.1%
GLUE
More free cash flow
GLUE
GLUE
$95.8M more FCF
GLUE
$99.8M
$3.9M
CURI

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CURI
CURI
GLUE
GLUE
Revenue
$19.2M
$12.8M
Net Profit
$-3.8M
$-27.1M
Gross Margin
Operating Margin
-17.6%
-258.3%
Net Margin
-19.7%
-212.1%
Revenue YoY
35.8%
38.5%
Net Profit YoY
-34.6%
-13.5%
EPS (diluted)
$-0.07

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CURI
CURI
GLUE
GLUE
Q4 25
$19.2M
Q3 25
$18.4M
$12.8M
Q2 25
$19.0M
$23.2M
Q1 25
$15.1M
$84.9M
Q4 24
$14.1M
$60.6M
Q3 24
$12.6M
Q2 24
$12.4M
Q1 24
$12.0M
Net Profit
CURI
CURI
GLUE
GLUE
Q4 25
$-3.8M
Q3 25
$-3.7M
$-27.1M
Q2 25
$784.0K
$-12.3M
Q1 25
$319.0K
$46.9M
Q4 24
$-2.8M
$13.4M
Q3 24
$-3.1M
Q2 24
$-2.0M
Q1 24
$-5.0M
Operating Margin
CURI
CURI
GLUE
GLUE
Q4 25
-17.6%
Q3 25
-24.5%
-258.3%
Q2 25
2.5%
-67.1%
Q1 25
0.5%
51.9%
Q4 24
-27.4%
21.4%
Q3 24
-25.8%
Q2 24
-20.6%
Q1 24
-30.4%
Net Margin
CURI
CURI
GLUE
GLUE
Q4 25
-19.7%
Q3 25
-20.4%
-212.1%
Q2 25
4.1%
-53.0%
Q1 25
2.1%
55.2%
Q4 24
-19.9%
22.2%
Q3 24
-24.3%
Q2 24
-16.4%
Q1 24
-42.0%
EPS (diluted)
CURI
CURI
GLUE
GLUE
Q4 25
$-0.07
Q3 25
$-0.06
Q2 25
$0.01
Q1 25
$0.01
Q4 24
$-0.05
Q3 24
$-0.06
Q2 24
$-0.04
Q1 24
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CURI
CURI
GLUE
GLUE
Cash + ST InvestmentsLiquidity on hand
$27.3M
$208.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$41.5M
$245.8M
Total Assets
$75.7M
$459.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CURI
CURI
GLUE
GLUE
Q4 25
$27.3M
Q3 25
$27.8M
$208.3M
Q2 25
$28.1M
$69.4M
Q1 25
$33.4M
$78.5M
Q4 24
$32.1M
$224.3M
Q3 24
$33.2M
Q2 24
$39.5M
Q1 24
$38.8M
Stockholders' Equity
CURI
CURI
GLUE
GLUE
Q4 25
$41.5M
Q3 25
$47.2M
$245.8M
Q2 25
$49.8M
$268.1M
Q1 25
$58.1M
$275.2M
Q4 24
$57.8M
$222.9M
Q3 24
$62.2M
Q2 24
$64.8M
Q1 24
$67.0M
Total Assets
CURI
CURI
GLUE
GLUE
Q4 25
$75.7M
Q3 25
$74.7M
$459.8M
Q2 25
$78.7M
$359.6M
Q1 25
$85.3M
$393.2M
Q4 24
$86.2M
$438.7M
Q3 24
$87.6M
Q2 24
$90.9M
Q1 24
$94.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CURI
CURI
GLUE
GLUE
Operating Cash FlowLast quarter
$4.0M
$100.4M
Free Cash FlowOCF − Capex
$3.9M
$99.8M
FCF MarginFCF / Revenue
20.5%
781.5%
Capex IntensityCapex / Revenue
0.1%
5.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$145.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CURI
CURI
GLUE
GLUE
Q4 25
$4.0M
Q3 25
$4.4M
$100.4M
Q2 25
$2.8M
$-34.7M
Q1 25
$1.9M
$-45.5M
Q4 24
$3.0M
$128.9M
Q3 24
$2.3M
Q2 24
$2.2M
Q1 24
$666.0K
Free Cash Flow
CURI
CURI
GLUE
GLUE
Q4 25
$3.9M
Q3 25
$99.8M
Q2 25
$-36.4M
Q1 25
$1.8M
$-47.1M
Q4 24
$128.7M
Q3 24
Q2 24
Q1 24
FCF Margin
CURI
CURI
GLUE
GLUE
Q4 25
20.5%
Q3 25
781.5%
Q2 25
-157.0%
Q1 25
12.2%
-55.4%
Q4 24
212.3%
Q3 24
Q2 24
Q1 24
Capex Intensity
CURI
CURI
GLUE
GLUE
Q4 25
0.1%
Q3 25
0.0%
5.1%
Q2 25
0.0%
7.3%
Q1 25
0.5%
1.9%
Q4 24
0.0%
0.3%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
CURI
CURI
GLUE
GLUE
Q4 25
Q3 25
Q2 25
3.56×
Q1 25
6.03×
-0.97×
Q4 24
9.59×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons